Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vance G Fowler

Showing results (291-300 of 426) with videos related to

Pageof 43
Sort By:
Antibiotics (Basel, Switzerland)|April 27, 2026
Virulence Phenotypes Differentiate Persistent vs. Resolving Isolates of Human <i>Staphylococcus aureus</i> BacteremiaLiana C Chan, Hong K Lee, Ling Wang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 16, 2018
Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream InfectionSarah B Doernberg, Thuy Tien Tram Tran, Steven Y C Tong, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 23, 2023
Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial PneumoniaJessica Howard-Anderson, Toshimitsu Hamasaki, Weixiao Dai, et al.
Annals of the American Thoracic Society|December 25, 2015
Potential Cost-effectiveness of Early Identification of Hospital-acquired Infection in Critically Ill PatientsEphraim L Tsalik, Yanhong Li, Lori L Hudson, et al.
Antimicrobial Agents and Chemotherapy|January 30, 2024
<i>In vitro</i> activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant <i>Acinetobacter baumannii</i> collected in U.S. hospitalsAlina Iovleva, Christi L McElheny, Erin L Fowler, et al.
JAMA|April 18, 2026
Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia: The FAST Randomized Clinical TrialRitu Banerjee, Lauren Komarow, Yixuan Li, et al.
Trials|November 13, 2025
Study protocol for a multicenter, multinational prospective randomized controlled trial comparing outcomes in subjects with Gram-negative bacteremia who have blood culture evaluation using Fast Antibiotic Susceptibility Testing vs. standard of care testing: the FAST trialRitu Banerjee, Lauren Komarow, Yixuan Li, et al.
Science Translational Medicine|August 9, 2023
Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogensJinshi Zhao, C Skyler Cochrane, Javaria Najeeb, et al.
Open Forum Infectious Diseases|June 24, 2026
Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Acute Bacterial Skin and Skin Structure InfectionsJessica Howard-Anderson, Toshimitsu Hamasaki, Lizhao Ge, et al.
Journal of Intensive Care|November 22, 2018
Evaluating the discriminating capacity of cell death (apoptotic) biomarkers in sepsisChristopher Duplessis, Michael Gregory, Kenneth Frey, et al.
Pageof 43

Showing results (291-300 of 426) with videos related to

Sort By:
Pageof 43
Antibiotics (Basel, Switzerland)|April 27, 2026
Virulence Phenotypes Differentiate Persistent vs. Resolving Isolates of Human <i>Staphylococcus aureus</i> BacteremiaLiana C Chan, Hong K Lee, Ling Wang, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 16, 2018
Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream InfectionSarah B Doernberg, Thuy Tien Tram Tran, Steven Y C Tong, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 23, 2023
Moving Beyond Mortality: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial PneumoniaJessica Howard-Anderson, Toshimitsu Hamasaki, Weixiao Dai, et al.
Annals of the American Thoracic Society|December 25, 2015
Potential Cost-effectiveness of Early Identification of Hospital-acquired Infection in Critically Ill PatientsEphraim L Tsalik, Yanhong Li, Lori L Hudson, et al.
Antimicrobial Agents and Chemotherapy|January 30, 2024
<i>In vitro</i> activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant <i>Acinetobacter baumannii</i> collected in U.S. hospitalsAlina Iovleva, Christi L McElheny, Erin L Fowler, et al.
JAMA|April 18, 2026
Fast Antimicrobial Susceptibility Testing for Gram-Negative Bacteremia: The FAST Randomized Clinical TrialRitu Banerjee, Lauren Komarow, Yixuan Li, et al.
Trials|November 13, 2025
Study protocol for a multicenter, multinational prospective randomized controlled trial comparing outcomes in subjects with Gram-negative bacteremia who have blood culture evaluation using Fast Antibiotic Susceptibility Testing vs. standard of care testing: the FAST trialRitu Banerjee, Lauren Komarow, Yixuan Li, et al.
Science Translational Medicine|August 9, 2023
Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogensJinshi Zhao, C Skyler Cochrane, Javaria Najeeb, et al.
Open Forum Infectious Diseases|June 24, 2026
Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Acute Bacterial Skin and Skin Structure InfectionsJessica Howard-Anderson, Toshimitsu Hamasaki, Lizhao Ge, et al.
Journal of Intensive Care|November 22, 2018
Evaluating the discriminating capacity of cell death (apoptotic) biomarkers in sepsisChristopher Duplessis, Michael Gregory, Kenneth Frey, et al.
Pageof 43